CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats

NeuroReport

Volumn 9, Issue 15, 1998, Pages 3397-3402

  Navarro, Miguel ^a   Chowen, Julie ^b   Rocio A Carrera M ^c   Del Arco, Lgnacio ^a,d   Villanúa, Maria A ^d   Martin, Yolanda ^a   Roberts, Amanda J ^c   Koob, George F ^c   Rodriguez De Fonseca, Fernando ^a  

^a Facultad de Psicologia   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cannabinoids; Dependence; Naloxone; Opiates; Receptors; SR 141716A; Withdrawal

Indexed keywords

CANNABINOID RECEPTOR ANTAGONIST; MORPHINE; OPIATE; RIMONABANT; CANNABINOID RECEPTOR; DRUG RECEPTOR; MESSENGER RNA; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC ANTAGONIST; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; ANIMAL; BRAIN LEVEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; MORPHINE ADDICTION; PHYSIOLOGY; WISTAR RAT; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN CHEMISTRY; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECEPTORS, OPIOID, MU; RNA, MESSENGER; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0032569520     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199810260-00012     Document Type: Article

References (25)

1. Herkenham M, Lynn AB, Johnson MR et al. J Neurosci 11, 563-583 (1991).
2. Matsuda LA, Bonner TI and Lolait SJ. J Comp Neurol 327, 535-550 (1993).
3. Kandel ER, Schwartz JH and Jessell TM. Principles of Neural Science, 3rd edn. Norwalk, CT: Appleton and Lange, 1991.
4. Tanda G, Pontieri FE and Di Chiara G. Science 276, 2048-2050 (1997).
5. Rodriguez de Fonseca F, Carrera MRA, Navarro M et al. Science 276, 2050-2054 (1997).
6. Chen J, Paredes W, Li J et al. Psychopharmacology 102, 156-162 (1990).
7. Koob GF, Robledo P, Markou A and Caine SB. The mesocorticolimbic in drug dependence and reward-a role for extended amygdala? In: Kalivas PW and Barnes CD, eds. Limbic Motor Circuits and Neuropsychiatry. Boca Raton, FL: CRC Press, 1993: 289-309.
8. Reisine T and Brownstein MJ. Curr Opin Neurobiol 4, 406-412 (1994).
9. Vela G, Ruiz-Gayo M and Fuentes JA. Neuropharmacology 34, 665-668 (1995).
10. Welch SP and Stevens DL. J Pharmacol Exp Ther 262, 10-18 (1992).
11. Matthes HW, Maldonado R, Simain F et al. Nature 383, 819-823 (1996).
12. Delfs JM, Kong H, Mestek A et al. J Comp Neurol 345, 46-68 (1994).
13. Howlett AC. Annu Rev Pharmacol Toxicol 35, 607-634 (1995).
14. Sim LJ, Selley DE, Dworkin SI and Childers SR. J Neurosci 16, 2684-2692 (1996).
15. Sim LJ, Hampson RE, Deadwyler SA and Childers SR. J Neurosci 16, 8057-8066 (1996).
16. Rinaldi-Carmona M,Barth F, Heaulme M et al. FEBS Lett 350, 240-244 (1994).
17. Gold LH, Stinus L, Inturrisi C and Koob GF. Eur J Pharmacol 253, 45-51 (1994).
18. Gellert VF and Holtzman SG. J Pharmacol Exp Ther 206, 536-546 (1978).
19. Navarro M, Rodriguez de Fonseca F, Alvarez E et al. J Neurochem 67, 1982-1991 (1996).
20. Rinaldi-Carmona M, Pialot F, Congy C et al. Life Sci 58, 1239-1247 (1996).
21. Bianchetti A, Guidice A, Nava F and Manara L. Life Sci 39, 2297-2303 (1986).
22. Maldonado R, Stinus L, Gold LH and Koob GF. J Pharmacol Exp Ther 261, 669-677 (1992).
23. Sim LJ, Selley, Xiao R and Childers SR. Eur J Pharmacol 307, 97-105 (1996).
24. Rubino T, Tizzoni L, Vigano D et al. NeuroReport 8, 3219-3223 (1997).
25. Comings DE, Muhleman D, Gade R et al. Mol Psychiatry 2, 161-168 (1997).